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Abstract
Purpose. Patients with fibromyalgia (FM) experience symptoms over a long period of time impacting their quality of life
(QoL). Patients are often treated in multimodal programmes that combine physical and cognitive treatment modalities.
Purpose of this study was to identify prognostic factors of effectiveness of a multimodal programme.
Method. A prospective study was performed with a group of 87 patients with FM who had participated in a multimodal
programme. The Revised Illness Perception Questionnaire (IPQ) and the Fibromyalgia Impact Questionnaire (FIQ) were
used. Criterion for clinically relevant improvement was a decline in total FIQ score of 12.5 points or more after the treatment
programme. Investigated determinants of improvement of QoL were patient characteristics, illness perceptions (IP) and
QoL at baseline.
Results. QoL of 34 patients with FM made a clinically relevant improvement after the programme. There was no difference
in age, number of years with pain, number of years diagnosed or IP compared to the group that did not improve. The group
of patients with an improved QoL after the programme reported severe impact on daily living, highest intensity of pain and
most depression at baseline.
Conclusions. Total FIQ score on QoL, intensity of pain, morning tiredness and depression can be used as prognostic factors
to pre-select patients with FM for a multimodal treatment. IP were not adequate to predict treatment outcome. An intensive
multimodal programme seemed most suitable for patients with severe symptoms and limitations.
Keywords: Fibromyalgia, prognostic factors, multimodal programme, illness perceptions, quality of life
Introduction
Fibromyalgia (FM) is a complex syndrome with
chronic widespread pain as a defining feature. Other
symptoms frequently reported include: sleep distur-
bance, irritable bowel, headache, excessive fatigue
and mood disorders [1]. FM is associated with
significant impairments on quality of life (QoL) and
function. The prevalence rates in western countries
vary from 2 to 3% and the syndrome affects mostly
women [2]. As with other pain syndromes the
aetiology appears to have physical, psychological,
behavioural, cognitive and environmental features in
patients with FM but the specific aetiology of FM is
still not completely understood [3–5]. Chronic pain,
such as in patients with FM, is the most common
cause of long-term disability and of high direct and
indirect costs to modern society [6].
There is a large diversity in treatments for FM.
Management of the different features of FM is often
combined in a multimodal programme. Lemstra and
Olszynski (2005) assessed the effectiveness of a
6-week during multidisciplinary rehabilitation pro-
gramme. They found significant changes in health
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status, average pain intensity, pain-related disability,
depressed mood, days in pain and hours in pain after
the intervention. At 15 months follow-up, all health
outcomes retained their significance except health
status [7]. A community patient education and
exercise programme, using a cognitive behavioural
approach for people with FM, reported short-term
effects on function and symptoms measured with the
FIQ and self-efficacy measured with the Arthritis
Self-efficacy scale. These improvements did not
sustain at the 8-month follow-up [8].
Meta-analysis shows that multimodal programmes
have beneficial short-term effects on key-symptoms
of FM such as pain, fatigue and depressed mood and
improve self-efficacy and physical fitness [9]. Some
positive effects were detected at follow-up (after 3–4
months) for physical fitness and self-efficacy. How-
ever, these positive effects declined with time (after
6–12 months) [9]. In general, the effects found are
rather small and the percentage of patients showing
significant clinical improvement is minimal [9–11].
It is not clear which specific treatment components
are effective and which patients benefit from which
treatment components [12]. Patients with FM are a
heterogeneous group with the subgroups being
identified based on their disease mechanisms (im-
munologic profile) [13], physical signs (quantitative
sensory testing) [14], psychological measures (pain
cognitions) [15] or a combination (pressure-pain
thresholds and mood and cognition) [16].
In the present article, we focus on psychological
measures and disability of the heterogeneous
group of patients with FM. Level of disability and
QoL of chronic pain patients can be predicted
based on patient specific characteristics, such as
pain intensity, cognitions and illness perceptions
(IP). The modifying effects of IP on the association
between impairments in body structures and func-
tions due to osteoarthritis (OA) and limitation in
activities in the lower extremities were investigated
in a study in patients with OA [17]. Patients who
strongly believed that OA had a major impact on
their functioning and who strongly believed in the
likely chronic duration of their OA also had an
increased risk to report more limitations than
expected from clinical and radiological assessments.
IP also have been described as prognostic factors
for determining prognosis in patients with low back
pain [18]. Patients with low back pain who
expected their back problem to last a long time,
who perceived serious consequences on their daily
lives and who held weak beliefs about the controll-
ability of their back problem were more likely to
have poor clinical outcomes after 6 months.
Cognitions like fear-avoidance beliefs, catastrophis-
ing and specific IP have been identified as
important patient specific characteristics and proven
to be better predictors of disability and QoL than
pain itself [19–22]. IP are beliefs that patients
hold about diseases. IP were first described by
Leventhal et al. in the Common Sense Model
(CSM) [23]. According to this model, patients
develop a cognitive representation that is used to
make sense of their illness experience. Research has
suggested that IP have common content and can be
ordered in five dimensions: identity, causes, con-
sequences, time line and cure-control [24]. IP are
thought to determine coping strategies and emo-
tional responses to the disease and are important in
directing the recovery process [23].
Research on prognostic factors for treatment
success in chronic pain syndromes have been studied
extensively in chronic low back pain (CLBP). Highly
distressed patients with strong feelings of disability,
who see their pain as an uncontrollable and highly
negative life event, derive less benefit from treat-
ment than other patients. Decreased negative emo-
tional responses to pain, decreased perceptions of
disability, and increased orientation toward self-
management during the course of treatment predict
favourable treatment outcome [25]. In another
study, Health Locus of Control belief was associated
with a successful treatment outcome in patients
with CLBP. Those patients with stronger internal
beliefs had gained more from the treatment, learned
their exercises better and had higher exercise
compliance during the follow-up period. Symptoms
of psychological distress were significantly associ-
ated with poorer accomplishments of the back
exercises [26].
A study with patients with CLBP in an outpatient
university based pain rehabilitation setting analysed
the relationship between self-reported psychological
factors (psychological distress, depression, self-effi-
cacy, self-esteem, fear of movement, pain cognitions
and coping reactions) and disability measured with
both performance tests and self-reports. This study
could not confirm strong relationships between these
two sets of variables [27]. Another CLBP study
showed that high scores of pain intensity, depression
and fear-avoidance beliefs may contribute to the
prediction of improvement after a rehabilitation
programme for patients with CLBP [28].
Little is known about prognostic factors for
positive response to multimodal treatment pro-
grammes for patients with FM. The aim of the
present study is to identify prognostic factors of
effectiveness for patients with FM participating in a
multimodal programme. In this study we explored
patient characteristics, IP and QoL of patients with
FM as possible predictors of treatment outcome.
Because negative cognitions are an important pre-
dictor of disability, we expect that patients with
negative IP’s will have a worse treatment outcome.

























































A prospective treatment study was performed;
patients were evaluated at baseline and post-treat-
ment (pre–post design) to determine if patient
characteristics (age, duration of pain, years diag-
nosed with FM), IP or initial scores on QoL were
predictors to success of the programme. The study
outline is presented in Figure 1.
Multimodal treatment programme
The multidisciplinary programme active living
with Fibromyalgia (MPF) combined self-manage-
ment, education and physical therapy [29]. The
programme comprised an educational part of seven
sessions and a physical therapy part of 25 sessions
(Figure 2). The educational part was aiming at:
cognitive restructuring, information on FM, goal-
setting, pacing, distraction and assertiveness training.
The goal of cognitive restructuring was changing
inadequate cognitions by educating patients about
pain mechanisms in FM and about the importance of
an active lifestyle. Self-management was promoted
by setting goals, pacing, distraction techniques and
assertiveness training.
The 25 sessions of physical therapy were aiming at:
behavioural changes using a graded activity pro-
gramme, relaxation and goal setting. The exercises
were performed according to the operant condition-
ing principles using a graded activity programme to
achieve behavioural change. Total duration of the
MPF programme was 17 weeks.
Study population
Patients were referred to the MPF programme by
their general practitioner or by a medical specialist.
They met the inclusion criteria considered by a nurse
specialist. Inclusion criteria were a diagnosis of FM
by a GP or rheumatologist, the patient demands no
further medical assessment, agrees with the purposes
of the programme, is mentally and physically able to
follow the programme and is motivated. Exclusion
criteria comprise the patient has already followed
a similar programme or is undergoing treatment
elsewhere at the moment. The patient were further-
more excluded when having cognitive disorders,
Figure 1. Study outline. *DFIQ¼ ‘Total FIQ score’ at post
treatment minus ‘total FIQ score’ at baseline.
Figure 2. Multidisciplinary programme active living with fibromyalgia (MPF).























































psychopathology, acute psychosocial problems, in-
surance claims or medical re-assessment, pain as a
consequence of malignancy, extreme fatigue, not
able to understand or speak Dutch or to function in a
group. Patients signed an informed consent form
before entering the study. Included patients were
clustered in a group of 8–12 patients for the
educational part; this group was later divided into
two separate groups for the physical therapy part.
Twenty physical therapy practices in the northern
provinces of the Netherlands implemented the MPF
programme. The physical therapists were responsible
for the treatment process and evaluation measure-
ments. Only questionnaires that were complete at
baseline and post treatment were included in the
analyses.
Questionnaires
Two questionnaires were used in this study; the
Fibromyalgia Impact Questionnaire (FIQ) and the
Revised Illness Perception Questionnaire (IPQ-R).
FIQ
QoL was evaluated with the FIQ. The FIQ measures
the impact of FM on patients’ lives, in terms of
symptoms and limitations. Overall it has credible
construct validity, reliable test–retest characteristics
and a good sensitivity in demonstrating therapeutic
change [27,28]. The FIQ was found to be the most
efficient instrument for discriminating and assessing
the impact of FM on QoL [30,31].
The FIQ is composed of 10 items. Patients were
asked to rate their status within the last week. The
first item includes 10 questions concerning physical
functioning, rated on a 4-point Likert type scale.
Items 2 and 3 report the number of days feeling good
(range 0–7) and number of days unable to work
(range 0–7). Item 4 through 10 are horizontal linear
scales where the patient rates; difficulty in doing their
job, level of pain, fatigue, morning tiredness, stiff-
ness, anxiety and depression (range 0–10).
Item 1–3 are normalised to 10 points. Total score
of the FIQ ranges from 0 to 100 points. The higher
the score, the more functional impairment and
symptoms are experienced. In this study, total FIQ
score was calculated by leaving item 3 out, because
most patients were unemployed.
IPQ-R-Dlv
The IPQ-R provides a psychometrically acceptable
quantitative assessment of the key components of
patients’ perceptions of illness [24]. The IPQ-R
English language version was shown to give good
internal reliability of the domains, good short and
longer-term retest reliability and sound discriminant
validity, known group and predictive validity in a
study population consisting of patients with a variety
of diseases (asthma, diabetes, rheumatoid arthritis,
acute pain, chronic pain, myocardial infarction,
multiple sclerosis (all from Auckland, New Zealand)
and HIV (from Brighton, United Kingdom) [24].
The English language version for rheumatoid arthri-
tis and the Dutch version for diabetes were used as
examples [www.uib.no/ipq] to construct the Dutch
language version for FM. The terminology ‘my
illness’ was changed into ‘my fibromyalgia’. The
Dutch language version of the IPQ-R has acceptable
psychometric properties [32].
The IPQ-R Dlv consists of nine domains. In the
first domain ‘illness identity’, patients are asked if
they experience a specific symptom (based on a total
of 14 possible symptoms) and whether they believe
this symptom is related to FM. The score on the
identity domain is calculated of the sum of the yes-
rated items related to FM.
The following seven domains of the IPQ-R Dlv are
scored on a 5-point Likert type scale (1–5): strongly
disagree, disagree, agree nor disagree, agree and
strongly agree. These domains include timeline
acute/chronic (perceptions of likely chronic duration
of the health problems); timeline cyclical (percep-
tions of likely variability of the health problems over
time); consequences (beliefs about illness severity
and impact on physical, social and psychological
functioning); personal control (belief in personal
control over the illness); treatment control (belief
in cure through treatment); illness coherence (com-
prehension or understanding of the illness); and
emotional representations (perception of negative
emotions generated by the illness).
High scores on the identity, timeline, conse-
quences and cyclical domains represent a negative
view of the illness. High scores on the personal
control, treatment control and coherence domains
represent positive beliefs about the controllability of
the illness and a personal understanding of the
condition. Finally, the causal domain is presented as
a separate section. It consists of 18 attribution items,
which are scored on the same Likert type scale. The
causal domain can be divided into four sub domains:
psychological attributions, risk factors, immunity and
accident or chance.
Data analysis
Data were analysed using SPSS 15.0. We divided
the population into two groups based on clinical























































outcome. A decrease in total FIQ score after the
programme means improvement in QoL. When FIQ
score was at least 12.5 points lower after the pro-
gramme compared to baseline, that difference was
considered as clinically relevant. This cut-off point
was based on the mean of within group changes of 17
clinical intervention studies all using the total FIQ
score as outcome parameter [33].
Age, the FIQ scores and scores on the IPQ
dimensions at baseline of the two groups were
compared using an independent sample t-test.
Number of years with pain and number of years
diagnosed were not normally distributed and there-
fore analysed with a Mann–Whitney test.
When the FIQ had more than three missing values
or the IPQ had more than five missing values or
these missing values were not randomly distributed,
the questionnaires were excluded from this study.
The remaining missing responses were imputed
using the sample median.
Results
In total, 87 patients randomly selected in 20 different
physiotherapy practices completed the IPQ at base-
line and the FIQ at baseline and post-treatment.
There were 42 participants who did not complete all
questionnaires until post-measurement. The missing
responses of the remaining 87 questionnaires were
imputed with the sample median. For IPQ at base-
line 1.7% of the answers was imputed with the
sample median. For the FIQ, 1.9% of the answers
was imputed at baseline and 4.4% was imputed after
the programme with the sample median.
Nine men and 78 women participated in the study,
which is consistent with population characteristics of
patients with FM. Mean age was 46 (SD12) years,
mean years with pain was 13 (SD 11) and the
patients were diagnosed with FM with a mean
duration of 3 (SD 5) years. The patient population
was divided in two groups based on clinical outcome.
Thirty-four patients improved in QoL because of a
decrease in total FIQ score of 12.5 points or more.
Fifty-three patients improved less than 12.5 points or
did not improve at all. An improvement of less than
12.5 points was not considered clinically relevant.
Therefore, all 53 patients were gathered in the group
that did not improve on QoL.
The two groups were compared at baseline on age,
years of pain, years diagnosed, IPQ scores and FIQ
scores, to analyse possible predictors of outcome
(Table I). Group 1 is the group who did not improve
their QoL; Group 2 did improve after the pro-
gramme. The mean age of the groups was compar-
able. Years of pain were higher and number of years
diagnosed lower in Group 2 but these differences
were not significant. The total FIQ score at baseline
was significantly higher in Group 2. Group 2 scores
on the FIQ dimensions were generally higher post
treatment, but only pain intensity, morning tiredness
and depression scores differed significantly com-
pared to before the programme. There were no
significant differences in baseline scores between the
two groups on the IPQ dimensions.
Discussion
The primary goal for this prospective non-controlled
treatment study was to identify prognostic factors for
patients with FM who benefit from a multimodal
programme. We expected IP to be a prognostic
factor, because negative IP have proven to be a
predictor of disability. This hypothesis could not be
confirmed in our study. Neither patient character-
istics like age, number of years with pain and number
of years diagnosed with FM were of predictive value.
There was, however a significant difference between
the two groups on their baseline scores of the FIQ.
‘Pain intensity’, ‘morning tiredness’, ‘depressed
mood’ and total FIQ score were significantly higher
at baseline for the group that improved the most in
QoL after the programme. These results imply that a
multimodal programme could specially benefit pa-
tients that have more severe problems prior to the
programme.
In a study with patients with CLBP, high scores of
pain intensity, depression and fear-avoidance beliefs
may contribute to the prediction of improvement
after a rehabilitation programme [28]. This is in line
with our finding of high scores of pain intensity and
depression before the programme in patients with
FM that report the most improvement after the
programme.
In several studies IP have been associated with
perceived limitations, disability and well-being [17–
23]. Patients with low back pain with negative IP
were more likely to have poor clinical outcome after
6 months [18]. However, a study with patients with
CLBP in a outpatient university based pain rehabi-
litation setting analysing the relationship between
psychological factors (psychological distress, depres-
sion, self-efficacy, self-esteem, fear of movement,
pain cognitions and coping reactions) and perfor-
mance based and self-reported disability, could not
confirm a strong relationship [27].
In our study IP had no predictive value for
effectiveness of a multimodal programme. The IP
of our study population were comparable to FM
populations in other studies; patients perceiving FM
to be chronic with serious consequences and
perceiving little personal control and little treatment
control [21,34]. However the IPQ-R Dlv we used























































was possibly not specific enough for the perceptions
patients with FM have. The IPQ-R is not a disease
specific questionnaire. We replaced the words ‘my
illness’ by the words ‘my fibromyalgia’. The authors
of the IPQ-R encourage researchers to make the
IPQ-R more disease specific by adding new items
[24]. Addition of FM specific items such as ‘FM is
caused by a rheumatic disease’, could have made
the questionnaire more sensitive. The current study
has some limitations to consider. ‘There are some
possible confounders (current level of activity,
medication, employment status) that were not taken
into analysis because of lack of this information. We
suggest that these factors will be included in future
research’. Possibly, a type II error occurred by a
floor effect in FIQ scores. Because of the chronic
nature of FM most patients will remain to experience
FM symptoms, meaning that FIQ scores will remain
relatively high. The purpose of the multimodal
programme is not to cure FM, but learning to cope
with FM. A study establishing norm scores for the
FIQ for patients with FM described an average score
of 57 points (or 63 when unemployed) [35]. Patients
that have higher FIQ scores at baseline are more
likely to decrease their scores and improve after the
programme.
Patient selection bias could be caused by the fact
that physical therapists working in the 20 practices
that implemented the MPF programme were res-
ponsible for collecting and sending the question-
naires. The selection of patients is therefore at
random and only completed questionnaires at base-
line and post treatment were used in this study.
Unfortunately, we had to exclude 42 participants
from our results who did not complete all ques-
tionnaires until post-measurement.
This study was a first attempt to identify factors of
success at a multimodal treatment programme for
patients with FM. We explored the possibility to look
at present patient characteristics and symptoms
before attending a treatment programme. This is
an important issue for further exploration because
matching specific patient characteristics to specific
treatment modalities could improve effectiveness of
treatment and could lower health costs.
Cognitions have proven to be important in
predicting disability and QoL. Therefore, cognitions
of patients should always be taken into consideration
Table I. Between group comparison of predictor variables at baseline.
Not improved Improved
Between group comparisonGroup 1 (N¼ 53) Group 2* (N¼34)
Mean (SD) Mean (SD) P value
Patient characteristics
Age 45.3 (12.7) 45.8 (10.7) 0.87
Number of years with pain 12.8 (9.4) 13.4 (13.0) 0.90
Number of years diagnosed 3.7 (5.9) 2.7 (3.7) 0.33
Quality of life (FIQ)
Physical functioning norm. score 6.4 (1.9) 6.2 (2.1) 0.61
Days feel good norm. score 6.1 (2.9) 6.1 (2.5) 0.98
Influence pain on work 6.8 (2.5) 7.6 (2.2) 0.15
Pain intensity 6.7 (1.9) 7.5 (1.7) 0.05*
Fatigue 7.4 (2.5) 8.0 (1.6) 0.17
Morning tiredness 7.1 (2.4) 8.4 (1.3) 0.01**
Stiffness 7.3 (2.2) 7.8 (1.7) 0.21
Depressed 4.0 (2.6 ) 5.5 (2.4) 0.01**
Anxiety 5.4 (2.9) 6.5 (2.4) 0.07
Total FIQ (- fiq3) 63.6 (14.5) 70.6 (10.7) 0.01**
Illness perceptions (IPQ)
Identity (0–14) 5.8 (2.2) 6.4 (2.2) 0.13
Timeline (6–30) 25.1 (3.8) 25.6 (3.5) 0.50
Timeline cyclical (4–20) 14.5 (3.3) 15.6 (2.6) 0.11
Consequences (6–30) 19.7 (4.0) 19.8 (4.9) 0.84
Personal control (6–30) 21.5 (3.8) 22.6 (3.6) 0.21
Treatment control (5–25) 17.4 (3.3) 16.7 (3.4) 0.37
Illness coherence (5–25) 12.9 (2.3) 12.8 (2.2) 0.76
Emotional report (6–30) 15.9 (4.2) 17.4 (5.5) 0.15
Attribution
Psychological attribution (6–30) 17.9 (5.3) 18.8 (4.9) 0.43
Risk factors (7–35) 14.8 (3.9) 15.5 (3.9) 0.43
Immunity (3–15) 6.3 (2,1) 6.7 (2.2) 0.50
Accident or chance (2–10) 5.4 (1.6) 4.8 (1.6) 0.11
*p50.05; **p50.01.























































in multimodal programmes for patients with FM.
Based on this study, IP did not seem valid to
preselect patients that benefit from intensive multi-
modal programmes. We think IP measured with the
IPQ-R Dlv were too generic to identify patient
subgroups and relate this to treatment outcome.
Measuring and investigating prognostic factors like
cognitions in future FM research and clinical
treatment should possibly focus on more specific
cognitions like pain catastrophising, somatisation,
acceptance of pain, kinesiophobia or fear avoidance
beliefs.
The results showed it could be clinically relevant
to consider the severity of symptoms and limitations
before a multimodal treatment programme and
prescribe intensive multimodal programmes to pa-
tients with the lowest QoL. In patients with FM with
less severe symptoms and limitations it could be
more effective if only those specific treatment
modalities are selected that provide for their specific
needs. These treatment modalities could be self-
management aspects (acceptance, goal-setting), phy-
sical fitness, relaxation, restructuring specific cogni-
tions or a combination of these treatment modalities.
The selection of treatment modalities for specific
subgroups of patients with FM can be an important
step in lowering health costs.
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